The nationwide experiment will initially include around 100,000 volunteers.
With the arrival of a new class of single-nucleotide editors, researchers can target the most common type of pathogenic SNP in humans.
The Scientist
Most Recent
Scientists extend the capabilities of the CRISPR-Cas system to include precise manipulations of RNA sequences in human cells.
Researchers identify 72 novel genetic variants associated with breast cancer risk.
Professionals in the genetics field generally support editing the genomes of somatic cells, mirroring public opinion, but diverge from nonexperts when it comes to germline editing.
At low doses, resveratrol enhanced human T-cell activity in vitro, while at high doses it interfered with cell signaling.
Plantings of non-GM refuges counter the development of resistance.
The EPA is now in charge of regulating the use of Oxitec’s strain of Aedes aegypti, genetically engineered to reduce populations of the insects.
A needle-free alternative to the finger-prick test would be a godsend for many sufferers of diabetes, but the industry has yet to clear the technological hurdles.
Researchers identified genes related to melanin levels in African populations.
Spark Therapeutics’s Luxturna would be the first approved therapy in the U.S. that replaces or repairs a defective gene inherited from one’s parents.
Popular Now
-
The Nutshell Estonia Offers Free Genetic Testing to Residents -
Daily News Human Brain Organoids Thrive in Mouse Brains After implantation, the tissue developed blood vessels and became integrated into neuronal networks in the animals’ brains.
-
The Nutshell New Ovarian Cancer Vaccine Shows Promise A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.
-
Daily News The Second March for Science a Smaller Affair Many cities around the globe, including Washington, DC, saw shrunken crowd sizes, and numerous events turned into rallies rather than processions.
Current Issue
© 1986-2018 The Scientist
